Economic modeling of the use of botulinum toxin A in a homogenous patient population based on real-life clinical practice: ULIS-II (The Upper Limb International Spasticity Study); the French perspective  by Dinet, J. et al.
Further reading
Viel E et al. Prise en charge des spasticite´s douloureuses: pourquoi
et comment utiliser les blocs locore´gionaux? Presse Med
2008:1793–801.
http://dx.doi.org/10.1016/j.rehab.2015.07.202
P042-e
Economic modeling of the use of
botulinum toxin A in a homogenous
patient population based on real-life
clinical practice: ULIS-II (The Upper
Limb International Spasticity Study);
the French perspective
J. Dinet a,*, D. Lambrelli b, M. Rabbani (Dr)a
a Ipsen Pharma, Boulogne-Billancourt, France
b Evidera Ltd
*Corresponding author.
E-mail address: jerome.dinet@ipsen.com (J. Dinet)
Objective To evaluate the real life practice of the use of
botulinum toxin A (BoNT-A) in post-stroke upper limb spasticity
and the economic consequences of fair comparisons of the dosing
between either abobotulinumtoxinA (Dysport1) or onabotuli-
numtoxinA (Botox1) or incobotulinumtoxinA (Xeomin1) in
France.
Methods ULIS-II is an 18-month, observational, prospective
study, conducted in 84 centers in 22 countries. France was the
major contributor with 14 centers. Of 456 adults with post-stroke
upper limb spasticity presenting for treatment with BoNT-A,
193 patients with the same injected limb segments ‘‘upper arm
and lower arm’’ were analyzed for the dose injected for one cycle of
BoNT-A. Treatment and concomitant interventions were in
accordance with routine local clinical practice. Sample size, mean
(SD)/median dose (min–max) in Unit for each BoNT-A and annual
cost per patient were calculated using the median dose adminis-
tered and considering no vial sharing. An injection interval of
12 weeks was simulated for all BoNT-A treatments and the France
listed public price was used to ascertain annual cost.
Results For the abobotulinumtoxinA group (n = 141) a mean
(SD)/median (min–max) dose of 665 U (280)/500 U (150–1500)
was injected, for the onabotulinumtoxinA group (n = 37) a mean
(SD)/median dose of 183 U (99)/200 U (50–500) was injected and
for incobotulinumtoxinA (n = 15), a mean (SD)/median dose of
235 U (108)/200 U (100-440) was injected. Based on a BoNT-A
injection interval of 12 weeks, the annual cost per patient in France
would be 1123s for abobotulinumtoxinA, 1784 s for onabotu-
linumtoxinA and 1784 s for incobotulinumtoxinA (based on
median doses).
Conclusions Considering the real life practice of BoNT-A injec-
tions and the comparison of treatment groups treated for the same
limb segment, this analysis suggests that the use of abobotuli-
numtoxinA would result potentially in a reduction in the
healthcare cost for the treatment of spasticity (37%) and that
more patients could be treated with abobotulinumtoxinA with a
given budget.
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Aim To evaluate efﬁciency of the tibialis posterior muscle
transfer in patients with peripheral palsy of foot levators, and to
determine occurrence of adverse effects on the static foot posture.
Patients and methods Fifteen patients were evaluated retrospec-
tively at amedian 90 months follow-up (8–219). Eight patients had
truncal paralysis (femoral fracture, knee sprain, total hip arthro-
plasty), 5 radicular (spinal trauma, disk hernia, lumbar surgery)
and 2 neuropathic paralysis. The tibialis posterior was transferred
on the tibialis anterior in 9 cases, on the second cuneiform twice,
three times on the peroneus brevis and once on the navicular. None
was associated to a Lambrinudi hind foot osteotomy. Collected
data concerned (a) function: orthotics need, walking distance, and
a satisfaction score (/4) (b) deﬁciencies: amplitude of active
dorsiﬂexion, dorsiﬂexion strength and plantar footprint and (c)
radiographic analysis, Djian angle and hindfoot alignment.
Results The eleven patients wearing orthotics were completely
weaned from it. Following the procedure, only one patient had a
limited walking distance (50–200 m). The mean satisfaction score
was 2/4 (3/4). Maximum dorsiﬂexion meanly reached the neutral
position (20 to 15); the arc of movement averaged 118(0–36)
during analytic testing and 4,58(0–10) when walking. Dorsiﬂexion
strength averaged 2,75 (0–5). Eleven patients had a normal plantar
footprint and4acavus foot.Djianangleaveraged122 (111–130)and
the hindfoot alignment angle was 5,38valgus. The Djian angle was
theonly angle tobe signiﬁcantlydifferent fromthe contralateral non
operated foot (P = 0,015), with a trend to cavus foot.
Discussion Tibialis posterior muscle is effective in foot-drop due
to peripheral paralysis. A ﬂat valgus foot does not appear to be a
long-term complication of this procedure. On the contrary, we
found a trend to cavus foot.
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The therapeutic use of botulinum toxin A in the treatment of
spasticity is well known. It inhibits the release of acetylcholine at
the neuromuscular junction and causing a chemical denervation
and paralysis of the muscle [1]. Its effects are usually locoregional
nevertheless rare systemic side effects are described in the
literature. We report a case of botulism-like syndrome.
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